Author/Authors :
Elbey, Bilal Dicle Üniversitesi - Tıp Fakültesi - İmmunoloj Anabilim Dalı, Turkey
Title Of Article :
Current treatment approaches in patients with ankylosing spondylitis
Abstract :
Ankylosing spondylitis (AS) is a chronic, inflammatory, rheumatic disease that mainly affects sacroiliac joints and spine. AS predominantly occurs more often in males and typically begins in the second or third decade. The mainstay of therapy in AS are nonsteroidal anti-inflammatory drugs, which reduce inflammation and pain. Disease modifying antirheumatic drugs (DMARD) did not have enough evidence to prove their effect in AS treatment. The use of DMARD may not sufficient to improve the treatment and symptoms. Currently, TNF-blockers such as, Golimumab Etanersept Adalimumab İnfliksimab have promising results in the treatment of AS. TNF-blockers improve the clinical signs and symptoms, and improve the patients’ physical function and quality of life. This manuscript is focused that Current pharmacological treatments in patients with ankylosing spondylitis.
NaturalLanguageKeyword :
Ankylosing spondylitis , treatment , tumour necrosis factor alpha inhibitor , disease modifying antirheumatic drugs
JournalTitle :
Dicle Medical Journal
